Article
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
Pharmacogenetics - 1 Feb 1996
Ratain M J, Mick R, Janisch L, Berezin F, Schilsky R L, Vogelzang N J, Kut M
Abstract excerpt
Amonafide is extensively metabolized, including conversion by N-acetylation to an active metabolite. Our previous studies have shown that fast acetylators of amonafide have increased toxicity, and we have recommended doses of 250 and 375 mg m-2 day-1 for 5 days, for fast and slow acetylators, res...
Topics
- Acetylation
- Adenine
- Adult
- Antineoplastic Agents
- Drug Administration Schedule
- Female
- Humans
- Imides
- Isoquinolines
- Leukocyte Count
- Leukopenia
- Male
- Middle Aged
- Models, Biological
- Naphthalimides
- Organophosphonates
- Phenotype
- Prospective Studies